Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement

Biomedicine and Pharmacotherapy

Volumn 61, Issue 6, 2007, Pages 299-305

  Brandau, Sven ^a,b   Suttmann, Henrik ^c  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

BCG immunotherapy; Bladder cancer; Granulocytes; Immune mechanism; Innate immunity; Mycobacterium bovis; NK cells; Tuberculosis

Indexed keywords

BCG VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 8;

ADJUVANT THERAPY; ARTICLE; BLADDER CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; META ANALYSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BCG VACCINE; CYTOKINES; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY; INFLAMMATION; URINARY BLADDER NEOPLASMS;

EID: 34547612220     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.05.004     Document Type: Article

References (75)

1. Mahairas G.G., Sabo P.J., Hickey M.J., Singh D.C., and Stover C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 178 (1996) 1274-1282
2. Lewis K.N., Liao R., Guinn K.M., Hickey M.J., Smith S., Behr M.A., et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis. 187 (2003) 117-123
3. Coley-Nauts H.C., and McLaren J.R. Coley toxins-the first century. Adv Exp Med Biol. 267 (1990) 483-500
4. Pearl R. Cancer and tuberculosis. Am J Hyg. 9 (1929) 97-100
5. Mathe G., Amiel J.L., Schwarzenberg L., Schneider M., Cattan A., Schlumberger J.R., et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1 (1969) 697-699
6. Morton D., Eilber F.R., Malmgren R.A., and Wood W.C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68 (1970) 158-163
7. Zbar B., Bernstein I.D., and Rapp H.J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 46 (1971) 831-839
8. Zbar B., and Rapp H.J. Immunotherapy of guinea pig cancer with BCG. Cancer 34 (1974) 1532-1540
9. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol. 116 (1976) 180
10. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. CA Cancer J Clin. 55 (2005) 10-30
11. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49 (2006) 466-474
12. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 169 (2003) 90-95
13. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 168 (2002) 1964-1970
14. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 174 (2005) 86-91
15. Lamm D.L., DeHaven J.I., Shriver J., Crispen R., Grau D., and Sarosdy M.F. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guérin for superficial bladder cancer. J Urol. 144 (1990) 65-67
16. Lamm D.L., DeHaven J.I., Shriver J., and Sarosdy M.F. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guérin versus intravesical bacillus Calmette-Guérin in superficial bladder cancer. J Urol. 145 (1991) 738-740
17. Lüftenegger W., Ackermann D.K., Futterlieb A., Kraft R., Minder C.E., Nadelhaft P., et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol. 155 (1996) 483-487
18. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 163 (2000) 1124-1129
19. Oosterlinck W., Solsona E., van der Meijden A.P., Sylvester R.J., Böhle A., Rintala E., et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol. 46 (2004) 147-154
20. Lamm D.L., van der Meijden P.M., Morales A., Brosman S.A., Catalona W.J., Herr H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol. 147 (1992) 596-600
21. van der Meijden A.P., Sylvester R.J., Oosterlinck W., Hoeltl W., and Bono A.V. Maintenance Bacillus Calmette-Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 44 (2003) 429-434
22. Saint F., Patard J.J., Irani J., Salomon L., Hoznek A., Legrand P., et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 57 (2001) 617-621
23. Orihuela E., Herr H.W., Pinsky C.M., and Whitmore W.F.J. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60 (1987) 326-333
24. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Hoeltl W., and Bono A.V. The side effects of Bacillus Calmette-Guérin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 44 (2003) 423-428
25. Watanabe E., Matsuyama H., Matsuda K., Ohmi C., Tei Y., Yoshihiro S., et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 52 (2003) 481-486
26. Thalmann G.N., Sermier A., Rentsch C., Mohrle K., Cecchini M.G., and Studer U.E. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol. 164 (2000) 2129-2133
27. Thalmann G.N., Dewald B., Baggiolini M., and Studer U.E. Interleukin-8 expression in the urine after bacillus Calmette-Guérin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol. 158 (1997) 1340-1344
28. Badalament R.A., Herr H.W., Wong G.Y., Gnecco C., Pinsky C.M., Whitmore W.F.J., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol. 5 (1987) 441-449
29. Brandau S., Riemensberger J., Jacobsen M., Kemp D., Zhao W., Zhao X., et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 92 (2001) 697-702
30. Riemensberger J., Bohle A., and Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol. 127 (2002) 20-26
31. Suttmann H., Riemensberger J., Bentien G., Schmaltz D., Stöckle M., Jocham D., et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66 (2006) 8250-8257
32. Ratliff T.L., Gillen D.P., and Catalona W.J. Requirement of a thymus-dependant immune response for BCG-mediated antitumor activity. J Urol. 137 (1987) 155-158
33. Ratliff T.L., Ritchey J.K., Yuan J.J.J., Andriole G.L., and Catalona W.J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 150 (1993) 1018-1023
34. Kavoussi L.R., Brown E.J., Ritchey J.K., and Ratliff T.L. Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 85 (1990) 62-67
35. Zhao W., Schorey J.S., Bong-Mastek M., Ritchey J., Brown E.J., and Ratliff T.L. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86 (2000) 83-88
36. de Reijke T.M., Vos P.C.N., Bevers R.F.M., de Muinck Keizer W.H., Kurth R., and Schamhart D.H.J. Cytokine production by the human bladder carcinoma cell line T24 in the presence of Bacillus Calmette-Guérin. Urol Res. 21 (1993) 349-352
37. Esuvaranathan K., Alexandroff A.B., McIntyre M., Jackson A.M., Prescott S., Chisholm G.D., et al. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol. 154 (1995) 572-575
38. de Boer E.C., de Jong W.H., van der Meijden A.P., Steerenberg P.A., Witjes F., Vegt P.D., et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res. 19 (1991) 45-50
39. Ludwig A.T., Moore J.M., Luo Y., Chen X., Saltsgaver N.A., O'Donnell M.A., et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res. 64 (2004) 3386-3390
40. Suttmann H., Lehan N., Bohle A., and Brandau S. Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guérin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect Immun. 71 (2003) 4647-4656
41. Böhle A., Gerdes J., Ulmer A.J., Hofstetter A.G., and Flad H.-D. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 144 (1990) 53-58
42. Prescott S., James K., Hargreave T.B., Chisholm G.D., and Smyth J.F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 147 (1992) 1636-1642
43. Böhle A., Nowc C., Ulmer A.J., Musehold J., Gerdes J., Hofstetter A.G., et al. Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol. 144 (1990) 59-64
44. Haaff E.O., Catalona W.J., and Ratliff T.L. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol. 136 (1986) 970-974
45. Prescott S., James K., Hargreave T.B., Chisholm G.D., and Smyth J.F. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 144 (1990) 1248-1251
46. Luo Y., Chen X., and O'Donnell M.A. Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol. 147 (2007) 370-378
47. O'Donnell M.A., Luo Y., Chen X., Szilvasi A., Hunter S.E., and Clinton S.K. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. J Immunol. 163 (1999) 4246-4252
48. Suttmann H., Jacobsen M., Reiss K., Jocham D., Bohle A., and Brandau S. Mechanisms of bacillus Calmette-Guérin-mediated natural killer cell activation. J Urol. 172 (2004) 1490-1495
49. Hawkyard S.J., Jackson A.M., James K., Prescott S., Smyth J.F., and Chisholm G.D. The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol. 147 (1992) 1399-1403
50. Luo Y., Chen X., Downs T.M., DeWolf W.C., and O'Donnell M.A. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol. 162 (1999) 2399-2405
51. Thanhäuser A., Böhle A., Schneider B., Reiling N., Mattern T., Ernst M., et al. The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother. 40 (1995) 103-108
52. Brandau S., Suttmann H., Riemensberger J., Seitzer U., Arnold J., Durek C., et al. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Clin Cancer Res. 6 (2000) 3729-3738
53. Brandau S., and Bohle A. Activation of natural killer cells by Bacillus Calmette-Guérin. Eur Urol. 39 (2001) 518-524
54. Mehmut M., Takeda K., Abe M., Ogata H., Hirose S., Okumura K., et al. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guérin treatment. Urol Int. 75 (2005) 80-87
55. Yamaguchi T., and Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 16 (2006) 115-123
56. Loskog A., Ninalga C., Paul-Wetterberg G., de la Torre M., Malmström P.U., and Totterman T.H. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 177 (2007) 353-358
57. Brandau S. Local and systemic immune suppression in bladder cancer. J Urol. 177 (2007) 12-13
58. Janeway C.A.J., and Medzhitov R. Innate immune recognition. Annu Rev Immunol. 20 (2002) 197-216
59. Brennan P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 83 (2003) 91-97
60. Tailleux L., Schwartz O., Herrmann J.L., Pivert E., Jackson M., Amara A., et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med. 197 (2003) 121-127
61. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun. 68 (2000) 6883-6890
62. Fricke I., Mitchell D., Mittelstädt J., Lehan N., Heine H., Goldmann T., et al. Mycobacteria induce IFN-{gamma} production in human dendritic cells via triggering of TLR2. J Immunol. 176 (2006) 5173-5182
63. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 (2006) 24-37
64. Lizee G., Radvanyi L.G., Overwijk W.W., and Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 12 (2006) 4794-4803
65. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 49 (2006) 790-797
66. Weiss G.R., O'Donnell M.A., Loughlin K., Zonno K., Laliberte R.J., and Sherman M.L. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother. 26 (2003) 343-348
67. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alfa-2b for superficial bladder cancer. J Urol. 172 (2004) 888-893
68. Arnold J., de Boer E.C., O'Donnell M.A., Böhle A., and Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother. 27 (2004) 116-123
69. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., Rodriguez R.H., Gomez J.M., Martin M.G., et al. Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 174 (2005) 1242-1247
70. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 89 (2002) 671-680
71. Mack D., Holtl W., Bassi P., Brausi M., Ferrari P., de Balincourt C., et al. The ablative effect of quarter dose bacillus Calmette-Guérin on a papillary marker lesion of the bladder. J Urol. 165 (2001) 401-403
72. Morales A., Chin J.L., and Ramsey E.W. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol. 166 (2001) 1633-1638
73. Kelley D.R., Ratliff T.L., Catalona W.J., Shapiro A., Lage J.M., Bauer W.C., et al. Intravesical bacillus Calmette-Guérin-therapy for superficial bladder cancer: Effect of bacillus Calmette-Guérin viability on treatment results. J Urol. 134 (1985) 48-53
74. Lamm D.L., Riggs D.R., Shriver J.S., vanGilder P.F., Rach J.F., and DeHaven J.I. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 151 (1994) 21-26
75. Colombel M., Saint F., Chopin D.K., Malavaud B., Nicolas L., and Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 176 (2006) 935-939